Factors influencing infarct size following experimental coronary artery occlusions.
D000818:Animals; D001794:Blood Pressure; D001949:Bretylium Compounds / Q000494:pharmacology; D003327:Coronary Disease / Q000150:complications*; D003402:Creatine Kinase / Q000032:analysis; D004285:Dogs; D004558:Electric Stimulation; D004562:Electrocardiography; D005934:Glucagon / Q000494:pharmacology; D006321:Heart / Q000187:drug effects*; D006339:Heart Rate; D007545:Isoproterenol / Q000494:pharmacology; D009203:Myocardial Infarction / Q000201:enzymology / Q000209:etiology*; D009206:Myocardium / Q000201:enzymology; D010042:Ouabain / Q000494:pharmacology; D010101:Oxygen Consumption; D011433:Propranolol / Q000494:pharmacology; D013610:Tachycardia
D001949:Bretylium Compounds; D010042:Ouabain; D005934:Glucagon; D011433:Propranolol; D003402:Creatine Kinase; D007545:Isoproterenol